Bennett I S, Brooks G, Broom N J, Calvert S H, Coleman K, François I
SmithKline Beecham Pharmaceuticals, Chemotherapeutic Research Centre, Betchworth, Surrey, UK.
J Antibiot (Tokyo). 1991 Sep;44(9):969-78. doi: 10.7164/antibiotics.44.969.
Structure-activity relationships in a series of (5R)-6-triazolylmethylene penems with potent beta-lactamase inhibitory activity are described. In most cases, their in vitro synergistic activity with amoxycillin is superior to that of clavulanic acid, sulbactam and tazobactam (YTR 830). Against an Escherichia coli TEM-1 infection in mice, the compounds showed a broad range of potencies; an optimum polarity was found, however, which gave maximum potency.
描述了一系列具有强效β-内酰胺酶抑制活性的(5R)-6-三唑基亚甲基青霉烯类化合物的构效关系。在大多数情况下,它们与阿莫西林的体外协同活性优于克拉维酸、舒巴坦和他唑巴坦(YTR 830)。在小鼠的大肠杆菌TEM-1感染模型中,这些化合物表现出广泛的效价;然而,发现了一个最佳极性,可产生最大效价。